An Integrative Approach to Drug Repositioning Using Decision Tree Based Machine Learning

NIH RePORTER · NIH · F31 · $46,036 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT Despite recent advances in life sciences and technology, the amount of money spent developing a single drug has stayed drastically expensive. Overall efficiencies have caused drug development to stay the same, with an average cost of $2.6 billion and 15 years to develop a single drug. Considering these challenges, there is an increased need for drug repositioning, in which new indications are found for existing or unapproved drugs. Here we introduce an approach that integrates only drug similarity metrics, such as side effect, structure, and target similarities, to identify novel indications for drugs. By focusing on drug similarity metrics, our proposed method allows for applications towards orphan molecules that presently have no primary indication. To improve upon the current methods of drug repurposing, we propose the developing of a computational approach that utilizes multiple data types within a machine-learning framework in order to predict indications a drug may treat. Based on the observations that similar drugs are used for similar indications, this method utilizes publicly available databases to identify associations between drugs, and integrates drug similarity data, as well as drug-target specific information, into a machine-learning framework in order to accurately predict indications for these drugs. Altogether, our method provides a novel, broadly applicable strategy that can identify novel indications, allowing for an accelerated and more efficient method for future drug development and repositioning efforts.

Key facts

NIH application ID
10112306
Project number
5F31LM013058-03
Recipient
WEILL MEDICAL COLL OF CORNELL UNIV
Principal Investigator
Jamal Elkhader
Activity code
F31
Funding institute
NIH
Fiscal year
2021
Award amount
$46,036
Award type
5
Project period
2019-03-01 → 2022-02-28